Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GLA-SE + MART-1 antigen |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GLA-SE | G100|TLR-4 agonist G100|glucopyranosyl lipid A stable emulsion | TLR4 Agonist 2 | GLA-SE is an immune adjuvant that binds to and activates toll-like receptor 4 (TLR4), leading to activation of innate immunity (PMID: 22147791). | |
MART-1 antigen | LB39-AA|SK29-AA | MART-1 antigen is a melanocyte differentiation antigen that is recognized by cytotoxic T cells (PMID: 9706977). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02320305 | Phase I | MART-1 antigen GLA-SE + MART-1 antigen | MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery | Completed | USA | 0 |